The Novo Nordisk Eli Lilly lawsuit moved from a private dispute to formal federal litigation on 21 July 2026, when Novo Nordisk Inc. filed suit against Eli Lilly and Company and Lilly USA, LLC in the United States District Court for the District of New Jersey. The complaint accuses Lilly of running a nationwide pattern of deceptive direct-to-consumer advertising for Zepbound (tirzepatide) and Mounjaro (tirzepatide), in violation of the Lanham Act and multiple state false advertising and unfair competition statutes.
According to Novo Nordisk, the campaigns at the center of the Novo Nordisk Eli Lilly lawsuit rely on outdated clinical comparisons that pit Lilly’s highest injectable doses against lower, less effective doses of Novo Nordisk’s own medicines, Wegovy® (semaglutide) and Ozempic® (semaglutide). The company says this framing creates a false impression of broad, product-level superiority for Lilly’s obesity and type 2 diabetes treatments, even though newer and more effective FDA-approved dosing options now exist.
Novo Nordisk states the litigation follows a formal cease-and-desist letter that it sent to Lilly, and that Lilly declined to withdraw or meaningfully revise the disputed advertisements. Millions of Americans living with obesity and type 2 diabetes are exposed to these campaigns, which Novo Nordisk says have run during widely viewed national sporting broadcasts as well as on TikTok and Facebook.
Novo Nordisk Eli Lilly Lawsuit Details: Zepbound vs. Wegovy® Ad Claims
The first thread of the Novo Nordisk Eli Lilly lawsuit centers on a Zepbound-versus-Wegovy® comparison. Per the complaint, Lilly’s ads compare the maximum tolerated Zepbound dose of 10 mg or 15 mg against a lower Wegovy® dose of 1.7 mg or 2.4 mg, while omitting the newer 7.2 mg dose of injectable Wegovy® that the FDA approved in March 2026. Novo Nordisk says that omission matters because the 7.2 mg dose demonstrated an average bodyweight reduction of about 19 percent, or roughly 47 pounds, in the STEP UP trial.
Novo Nordisk further argues this specific comparison is misleading because no head-to-head clinical trial has ever directly compared the highest approved doses of Zepbound and Wegovy®. The complaint notes that this consumer-facing campaign has aired during major global sporting broadcasts and across TikTok and Facebook, which Novo Nordisk says has contributed to widespread confusion among consumers regarding which treatment is actually more effective at approved, top-tier doses.
A second and related claim in the Novo Nordisk Eli Lilly lawsuit involves Mounjaro and Ozempic®. Novo Nordisk alleges that Lilly’s advertising compares Mounjaro at its highest 15 mg dose against a lower, 1 mg dose of injectable Ozempic®, despite the FDA having approved a higher maintenance dose of Ozempic® (2 mg) more than four years earlier. Novo Nordisk contends that leaving out the approved 2 mg maintenance dose leaves consumers with an incomplete and outdated picture of Ozempic’s demonstrated efficacy, and that the comparison is structured to favor Lilly’s product regardless of current clinical evidence.
Novo Nordisk Eli Lilly Lawsuit Seeks Injunction and Corrective Advertising
Through this filing, Novo Nordisk is asking the court for a permanent injunction that would require Lilly to withdraw the disputed comparative advertisements across every platform where they appear, along with a court-ordered corrective advertising campaign. Novo Nordisk has also notified Lilly that, absent a voluntary withdrawal of the ads, it intends to file a separate motion in the coming days seeking a preliminary injunction to immediately halt the campaigns, citing evidence that consumers are being confused and misled.
As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions.
John F. Kuckelman, senior vice president and Group General Counsel at Novo Nordisk
Clinical Evidence Behind the Novo Nordisk Eli Lilly Lawsuit
The clinical foundation Novo Nordisk cites throughout the Novo Nordisk Eli Lilly lawsuit is the STEP UP trial, a 72-week study that evaluated once-weekly Wegovy® 7.2 mg against placebo and against Wegovy® 2.4 mg, used alongside lifestyle intervention, in 1,407 adults with obesity (a BMI of 30 kg/m² or greater) who did not have diabetes. At 72 weeks, mean weight loss with Wegovy® 7.2 mg reached approximately 18.8 percent, or about 47 pounds, compared with 3.9 percent, or roughly 10 pounds, for placebo. The most frequently reported adverse reactions with Wegovy® 7.2 mg included nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss, and flatulence.
What the Novo Nordisk Eli Lilly Lawsuit Means for the GLP-1 Market
The outcome of the Novo Nordisk Eli Lilly lawsuit could shape how GLP-1 manufacturers are permitted to frame comparative advertising going forward, particularly as newer, higher-strength doses continue to reach the market on both sides of the obesity and type 2 diabetes treatment category. A ruling favoring Novo Nordisk could force Lilly to overhaul active national campaigns and issue corrective messaging, while a preliminary injunction, if granted, could halt the disputed ads well before the underlying case is resolved.
